Please assess the completion status of the following clinical trial:

Trial Title: Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing clinically driven, non-emergent coronary angiography or intervention in our institution were eligible for inclusion if their serum creatinine concentration was ≥1.4 mg/dl (124 μmol/l) and/or their creatinine clearance was \<60 ml/min on their most recent sample drawn within 1 month of the planned procedure~Exclusion Criteria:~* Circulatory shock for any reason, systolic blood pressure \<95 mm Hg~* Known acute renal failure~* End-stage renal disease requiring dialysis~* Intravascular administration of a contrast medium within the previous 10 days~* Anticipated re-administration of contrast medium within the following 6 days~* Inability to administer intravenous hydration at least 4 h before the procedure or study medication at least 30 min before the procedure~* Primary intervention for acute infarction with ST elevation~* A procedure performed within 2 h of acute hospital admission

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Iloprost
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).